The occurrence of immune disorders including CRS and hemophagocytic lymphohistiocytosis among the most-frequently reported AEs in axi-cel-related ICSRs was highly expected since they have been frequently observed in axi-cel preapproval clinical trials [10,44] and seem to be the consequence of cytokine release, which occurs initially because of T-cell activation with IL-6 release and later because of the death of leukemic cells and of the ensuing macrophage activation [16,45,46]. The gene discussed is IL6; the disease is immune system disorder.